cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Three new REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes cagrisema phase 3 results 2024

But all of these improvements are highly individual, strongly influenced by nutrition, movement, sleep, stress, and existing medications, and dependent on correct use, appropriate dose, and adequate monitoring

For best results, follow with a soothing mask or hydrating serum

No worldwide marketing authorization, FDA IND status, WADA class S2

JAMA 303:14101418 Pratley RE, Nauck M, Bailey T et al (2010) Liraglutide vs sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Key clinical benefits: Breaks the plateau: It provides the extra support needed to restart weight loss when your body has adapted to the 2.4mg maintenance dose

Compounded GLP-1s from a licensed pharmacy should be consistent batch to batch